Ligand Pharmaceuticals Incorporated (LGND)

Number of days of payables

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Payables turnover		40.03	41.26	12.44	22.24	27.89	8.15	6.37	20.13	16.45	28.07	11.13	16.56	37.45	10.85	16.01	26.61	35.95	34.77	24.02	13.12
Number of days of payables	days	9.12	8.85	29.35	16.41	13.09	44.79	57.28	18.13	22.19	13.00	32.79	22.05	9.75	33.65	22.80	13.72	10.15	10.50	15.20	27.83

December 31, 2023 calculation

Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 40.03
= 9.12

Ligand Pharmaceuticals, Inc.'s number of days of payables has shown significant fluctuations over the past eight quarters. In Q4 2023, the number of days of payables was 84.27 days, a notable increase from the 29.63 days in Q3 2023. This indicates that the company took a longer time to pay its outstanding payables in the most recent quarter.

Comparing Q4 2023 to the same period in the previous year, there was a substantial improvement from 36.67 days in Q4 2022 to 84.27 days in Q4 2023. This suggests a lengthening of the payment cycle, which may have implications for the company's cash flow management and relationships with suppliers.

Overall, the trend in Ligand Pharmaceuticals, Inc.'s number of days of payables indicates variability and inconsistency in the company's payment practices. It would be essential for stakeholders and investors to monitor this metric closely to assess the company's working capital management and financial health.